Skip to main content
. 2023 Nov 27;36(Suppl 1):46–51. doi: 10.37201/req/s01.11.2023

Table 2.

Summary of recommendations in the ESCMID, IDSA and SEIMC guidelines for the treatment of infections due to carbapenemase producing Enterobacterales. Dosages of the different antimicrobials are those included in the Summary of Product Characteristics (SmPC).

Society
Year of publication
Carbapenemase type
KPC OXA-48 MBL
ESCMID
2021
Ceftazidime–avibactam*
Meropenem–vaborbactam
Ceftazidime-avibactam Ceftazidime–avibactam + aztreonam
Cefiderocol
Non-severe infection: Aminoglycosides (UTI) or tigecycline (not in bacteraemia /pneumonia)
IDSA
2022
Ceftazidime–avibactam
Meropenem–vaborbactam
Imipenem–relebactam
Ceftazidime-avibactam Ceftazidime–avibactam + aztreonam
Cefiderocol
UTI →Aminoglycosides, cefiderocol, meropenem Abdominal →Tigecycline, eravacycline
SEIMC
2022
Ceftazidime–avibactam
Meropenem–vaborbactam
Ceftazidime-avibactam Ceftazidime–avibactam + aztreonam
Cefiderocol
Alternative →Combined therapy (meropenem, colistin, tigecycline, aminoglycosides…)

UTI: urinary tract infection.